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Involvement of PPARc in the antitumoral action of
cannabinoids on hepatocellular carcinoma
D Vara1, C Morell1, N Rodrı´guez-Henche1 and I Diaz-Laviada*1
Cannabinoids exert antiproliferative effects in a wide range of tumoral cells, including hepatocellular carcinoma (HCC) cells. In
this study, we examined whether the PPARc-activated pathway contributed to the antitumor effect of two cannabinoids,
D9-tetrahydrocannabinol (THC) and JWH-015, against HepG2 and HUH-7 HCC cells. Both cannabinoids increased the activity
and intracellular level of PPARc mRNA and protein, which was abolished by the PPARc inhibitor GW9662. Moreover, genetic
ablation with small interfering RNA (siRNA), as well as pharmacological inhibition of PPARc decreased the cannabinoid-induced
cell death and apoptosis. Likewise, GW9662 totally blocked the antitumoral action of cannabinoids in xenograft-induced HCC
tumors in mice. In addition, PPARc knockdown with siRNA caused accumulation of the autophagy markers LC3-II and p62,
suggesting that PPARc is necessary for the autophagy flux promoted by cannabinoids. Interestingly, downregulation of the
endoplasmic reticulum stress-related protein tribbles homolog 3 (TRIB3) markedly reduced PPARc expression and induced p62
accumulation, which was counteracted by overexpression of PPARc in TRIB3-knocked down cells. Taken together, we
demonstrate for the first time that the antiproliferative action of the cannabinoids THC and JWH-015 on HCC, in vitro and in vivo,
are modulated by upregulation of PPARc-dependent pathways.
Cell Death and Disease (2013) 4, e618; doi:10.1038/cddis.2013.141; published online 2 May 2013
Subject Category: Cancer Metabolism
Hepatocellular carcinoma (HCC) is the most frequent primary
solid tumor of the liver, and it is estimated to account for 5% of
all malignant neoplasias.1,2 Its aggressiveness and extensive
dissemination lead to poor patient prognosis. Although there
has been a great research effort made in order to come up
with efficient therapeutic strategies, the incidence and
mortality of HCC have increased in the United States and
Europe in the past decade and therefore innovative research
findings are necessary to understand the etiology of cancer
and to improve the treatment and survival of patients.
Cannabinoids are bioactive lipids that have been shown to
modulate many physiological and pathological conditions. In
particular, it has been previously described that cannabinoids
arrest cell proliferation, reduce cell migration and inhibit
angiogenesis, and therefore, cannabinoid-like compounds
offer a therapeutic potential for the treatment of many types of
cancer.3–5 Although the well-defined cannabinoid receptors
are theGPCR receptor typesCB1 andCB2, cannabinoidsmay
impact other putative targets such as nuclear receptors
PPARs.6,7 PPARs are ligand-activated transcription factors,
which belong to the nuclear receptor superfamily and mediate
several physiological functions, among which the best
characterized are lipid metabolism, energy balance and anti-
inflammation.8 There are three PPAR subtypes: alpha, delta
(also known as beta) and gamma, all of which have long been
known to be expressed in the liver, although at different
levels.9 PPARg exists in two major isoforms (g1 and g2) that
arise by differential transcription start sites and alternative
splicing,10 albeit PPARg1 expression is very low in most
tissues including the liver. PPARg is involved in liver lipid
synthesis and storage, and despite its relatively low levels in
healthy liver it has a relevant role in several liver pathologies
such as liver steatosis, fibrosis and HCC. Although the role of
PPARg in the development of liver diseases with different
aetiologies has led to controversial results, there is a general
consensus about the fact that increased PPARg activity can
counteract the occurrence and progression of cancer in the
liver. Several PPARg ligands have been shown to reduce
HCC cell proliferation and migration through PPARg activa-
tion.11–15 Moreover, recent findings using PPARg knockout
mice suggest that PPARg reduces HCC carcinogenesis and
acts as a tumor-suppressor gene in the liver.16 Many current
lines of evidence indicate that there is a cross talk between
death signalling pathways and PPARg activity in several
cancer cell types.17 It has been demonstrated that the
synthetic cannabinoidWIN 55,212-2 (WIN) induces apoptosis
in the HCC HepG2 cell line, which is associated with an
increase in PPARg expression.18 We have previously
described that the cannabinoids D9-tetrahydrocannabinol
(THC), the main psychoactive component of the Cannabis
sativa plant, and JWH-015, a synthetic selective ligand of
CB2, exert antiproliferative effects and induce autophagy on
theHCC cell lines HepG2 andHuH-7.19 As cannabinoids have
well-known palliative effects on some cancer-associated and
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chemotherapy-related symptoms, and they are being ther-
apeutically used for this purpose, it is necessary to further
study the antitumoral properties of cannabinoids for a better
management of those compounds. In this study, we investi-
gated whether PPARg is involved in the antiproliferative effect
of cannabinoids on HCC cells and its relationship with the
previously identified signalling pathways.
Results
The cannabinoids THC and JWH-015 activate PPARc in
HCC cells. To investigate the role of PPARg in the
mechanism of action of cannabinoids on HCC cells, we
treated HepG2 cells with the cannabinoids THC and JWH-
015, after which PPARg expression was examined using
RT-PCR and western blot. As shown in Figure 1a, there was
a peak of PPARg mRNA at 1-h treatment with both
cannabinoids and a further decline at 24 h. Likewise, PPARg
protein expression increased until 3 h and then decreased at
8 h (Figure 1b). As a further proof of PPARg induction, we
measured the PPARg target CD36 to confirm PPARg
activation. As shown in Figure 1c, THC and JWH-015
produced an increase in CD36 mRNA levels with a peak at
6 h of treatment. Lipid accumulation in liver cells is
considered an indicator of PPARg activation. Therefore, we
measured neutral lipid content in HepG2 and HUH-7 cells by
Oil Red O staining. Neutral lipid accumulated in both HepG2
and HUH-7 cells after THC and JWH-015 treatment. The
increase in Oil Red O staining was prevented by pretreat-
ment with the PPARg antagonist GW9662, confirming the
involvement of PPARg in neutral lipid accumulation and
PPARg activation after cannabinoids treatment (Figure 2a).
Confocal microscopy of HepG2 cells treated with THC and
JWH-015 also showed a neutral lipid accumulation within the
cell (Figure 2c). Therefore, these data demonstrated that
cannabinoids treatment activates PPARg in HCC cells.
The activation of PPARg by cannabinoids may be
performed by direct binding to the receptor or by intracellular
signalling cascades that may lead indirectly to PPARg
activation. The mechanism of action of THC on PPARg has
been extensively studied by O’Sullivan and Kendall,20 but it is
unknown if JWH-015 can activate PPARg directly. To
investigate whether JWH-015 joined PPARg, we performed
a binding assay using HeLa cells with a reporter luciferase
gene. However, JWH-015-induced PPARg activation was not
due to an agonist activity of the compound, as JWH-015 was
not able to bind to the ligand-binding domain of PPARg in the
in vitro assay (Figure 2c), suggesting that PPARg activation
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Figure 1 Cannabinoid-induced PPARg increase in HCC cells. (a) HepG2 cells were treated with D9-tetrahydrocannabinol (8 mM) or JWH-015 (8mM) for different times
and PPARg mRNA levels were determined by quantitative PCR. Results are shown as the mean±S.E. (n¼ 5; **Po0.01 as compared with control cells by Student’s t-test).
(b) HepG2 cells were incubated either with THC (8mM) or with JWH-015 (8 mM), and PPARg protein levels were detected by western blot. Nucleoporin levels are shown as
loading control. The image is representative of three different experiments performed in duplicate. (c) HepG2 cells were incubated with THC (8mM) or JWH-015 (8mM) for
different times and CD36 mRNA levels were determined by quantitative PCR
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must be happening indirectly through signaling pathways
activated by cannabinoids.
AMPK and PPARc are two independent pathways
activated by cannabinoids. We have previously shown
that THC and JWH-015 stimulate autophagy on HCC cells
through two different pathways: (i) activation of adenosine
monophosphate-activated kinase (AMPK) via CaMKKb, and
(ii) ER stress with upregulation of tribbles homolog 3 (TRIB3)
and subsequent inhibition of the serine–threonine kinase Akt/
mammalian target of rapamycin C (Akt/mTORC1) axis.19
Furthermore, AMPK has been shown to participate in
modulating the activity of PPARg,21 thus providing a possible
mechanism for cross talk between the signaling pathways
activated by cannabinoids. PPARg phosphorylation by AMPK
represses both the ligand-dependent and independent trans-
activating function of the receptor. Therefore, we examined
whether the activities of these molecules by cannabinoids
were coordinately regulated. To investigate the relationship
between these two pathways, we knocked down AMPK and
measured PPARg levels after cell treatment with THC and
JWH-015. Both cannabinoids, THC and JWH-015, were able
to increase PPARg levels even when AMPK was absent
(Figure 3a). These findings indicate that AMPK is not
necessary for PPARg induction by cannabinoids. Moreover,
PPARg is not necessary for AMPK activation by cannabi-
noids, as downregulation of PPARg did not reverse the
increase in AMPK phosphorylation produced by THC or
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Figure 2 D9-Tetrahydrocannabinol and JWH-015 increase intracellular neutral lipid content in HCC cells. (a) HepG2 cells were incubated in the presence of increasing
concentrations of THC or JWH-015 for 24 h, and intracellular neutral lipid content was measured by Oil Red O stain as indicated in the Materials and Methods section, and
normalized to cell viability performed by MTT. Data are the mean±S.E. of three different experiments performed in duplicate. (b) HepG2 cells were treated with 8 mM THC or
8mM JWH-015 for 24 h and neutral lipid was detected by confocal immunofluorescence. Nuclei were stained with 40,6-diamidino-2-phenylindole. The image is representative
of three different experiments. (c) The binding capacity of JWH-015 to PPARg was investigated using the HeLa reporter cell lines, HG5LN GAL4-PPARg. HeLa cells were
treated with JWH-015 (8mM) and binding to PPARg was estimated by luciferase activity (relative light units normalized against the reference compound BRL49653) and
expressed as percentage relative to 1 mM of the classical agonist Rosiglitazone (Rosi)
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JWH-015 (Figure 3b). Therefore, these data suggest that
AMPK and PPARg are two independent pathways activated
by cannabinoids in HCC.
The TRIB3 protein regulates PPARc expression in HCC
cells. To investigate whether PPARg induction was asso-
ciated with the second mechanism by which cannabinoid
induced cell death (ER stress/Akt/mTORC1 axis), we
analysed this pathway in cells in which PPARg was
genetically blocked. However, PPARg knockdown did not
modify the inhibition of the Akt pathway and S6 phosphoryla-
tion or the increase in eIF2a phosphorylation, which we had
previously reported to be modified after cannabinoids
treatment (Figure 3b).
The intracellular adaptor TRIB3, a human homolog of
Drosophila tribbles, has been found to interact with a variety of
signalling molecules to regulate diverse cellular functions
including cell proliferation, migration and morphogenesis by
participating in protein complex assembly. In the liver, it
functions as a negative regulator of the serine–threonine
kinase Akt. We have previously shown that TRIB3 links
cannabinoid-induced ceramide production and endoplasmic
reticulum stress with Akt inhibition and autophagy in HCC
cells.19 Recent research has shown that in 3T3-L1 adipocytes
TRIB3 interacts with PPARg to modulate its transcriptional
activity.22 To investigate the role of TRIB3 in the action
mechanism of cannabinoids, HCC cells were transfected with
selective TRIB3 siRNA, treated with THC or JWH-015, and
examined for PPARg protein and mRNA expression. As
shown in Figure 3c, when TRIB3 was knocked down, levels of
PPARgwere virtually undetectable, both in control cells and in
cannabinoid-treated cells, being even more effective than
PPARg silencing. This means that TRIB3 is necessary for
PPARg expression and suggests a new PPARg regulatory
pathway to be explored in further research.
PPARc contributes to cannabinoid-induced autophagy.
Owing to recent data about the involvement of PPARg in
autophagy23,24 and as this process is necessary for the
antitumoral action of cannabinoid,19,25 we wondered whether
PPARg receptor might also have a role in the autophagy
induced by cannabinoids on HCC cells. To investigate this
effect, we analyzed LC3-II levels, a hallmark of autophagy, in
cannabinoid-treated cells. As shown in Figure 4, THC and
JWH-015 induced an increase in LC3II, as was expected,
measured by western blot (a) or confocal microscopy (b).
Surprisingly, knocking down of PPARg increased LC3II even
in the control cells. Likewise, cells treated with cannabinoids
showed higher LC3II levels when PPARg was knocked down
than when cells were transfected with the control siRNA. To
investigate whether this increase was caused by an
augmented activation of autophagy, levels of the signal
adaptor protein p62, an autophagosome cargo that is
Figure 3 TRIB3 is required for PPARg activation. (a) HepG2 cells were
transfected with control siRNA (siControl) or AMPK selective siRNA (siAMPK) and
incubated with THC (8 mM) or JWH-015 (8 mM) for 3 h, after which levels of PPARg
were detected by western blot. (b) HepG2 cells were transfected with control siRNA
(siControl) or PPARg selective siRNA (siPPARg) and incubated with THC (8 mM) or
JWH-015 (8 mM) for 24h, after which levels of phosphorylated forms of AMPK, AKT,
S6 and eIF2a were determined by western blot. (c) HepG2 cells were transfected
with control siRNA (siControl) or TRIB3 selective siRNA (siTRIB3) and incubated
with THC (8 mM) or JWH-015 (8mM) for 3 h, after which PPARg levels were
determined by western blot and quantitative PCR. Levels of TRIB3 mRNA
measured by quantitative PCR in siControl and siTRIB3-treated cells are shown
under the western blot. Data are the mean±S.D. of two experiments performed by
triplicate. Tubulin levels are shown as a loading control of western blots. The images
are representative of three different experiments
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eliminated by autophagy and accumulates when autophagy
is deficient, were measured in control RNA-transfected cells
and in PPARg siRNA-transfected cells. As observed in
Figure 4a, levels of p62 protein increased when PPARg
was silenced in control cells compared with cannabinoid-
treated cells. These results indicate that in PPARg-depleted
cells, autophagy is not active, but it is blocked after
autophagosome formation, and then p62 accumulates. If
TRIB3 is responsible for PPARg expression, then PPARg
overexpression in TRIB3-depleted cells should reverse p62
accumulation. Figure 4c shows that this is the case, as p62
does not accumulate in TRIB3-silenced cells in which PPARg
overexpression was induced by a mammalian expression
vector, indicating that PPARg is responsible for the autopha-
gosome blockage. Likewise, PPARg overexpression in
TRIB3-silenced cells restored the caspase 3 cleavage
(Figure 4c).
Autophagosome accumulation can occur for two reasons:
(i) autophagosomes are not fused with lysosomes or/and
(ii) lysosomes do not work correctly. As there are no data about
the participation of PPARg in the autophagosome–lysosome
fusion, but there are findings showing that PPARg regulates
lysosomal proteases,26,27 we decided to investigate this
option. Lysosomes are the key degradative compartments of
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Figure 4 PPARg participates in autophagy induction. (a) HepG2 cells were transfected with siRNA control or selective for PPARg (siControl or siPPARg) and treated with
THC 8 mM or JWH-015 8 mM and PPARg and p62 levels, microtubule-associated protein 1 light chain 3a non-lipidated (LC3-I) and lipidated (LC3-II) forms, LAMP-2 protein, as
well as procathepsin and cathepsil L, procathepsin and cathepsin D, were detected by western blot. Tubulin levels are shown as loading control. A representative western blot
of three different experiments is shown. (b) HepG2 cells were transfected with siRNA control or selective for PPARg (siControl or siPPARg), treated with THC 8mM or JWH-
015 8 mM for 24 h, and LC3 was detected by confocal immunofluorescence. Nuclei were stained with 40,6-diamidino-2-phenylindole. (c) HepG2 cells were transfected with
scramble (SiControl) or TRIB3 siRNA (SiTRIB3). At the same time, cells were transfected with an empty vector or PPARg overexpression vector as indicated in the Materials
and Methods section. After 48 h, cells were treated with DMSO (control), THC 8 mM or JWH 8 mM for 24 h and PPARg, p62, procaspase 3 and Tubulin were measured by
western blot. Images are representative of three different experiments. Levels of TRIB3 mRNA measured by quantitative PCR in siControl and siTRIB3-treated cells are shown
under the western blot. (d) Scheme of the proposed mechanism of cannabinoid-induced HCC cell death. Cannabinoid treatment stimulates autophagy via two different
mechanisms: (i) activation of AMPK or (ii) upregulation of tribbles homolog 3. TRIB3 induces subsequent inhibition of the serine–threonine kinase Akt/mammalian target of
rapamycin C (Akt/mTORC1) axis or upregulation of PPARg. Stimulation of autophagy by cannabinoids leads to HCC apoptosis and cell death
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the cell, because they are acidic organelles filled with
hydrolases. Among the lysosomal hydrolases, proteases,
especially cathepsins, have a major role. Similar to other
proteases, the cathepsins are synthesized as inactive
proenzymes and are activated by proteolytic removal of the
N-terminal propeptide. As shown in Figure 4a, THC and JWH-
015 increased the levels of cathepsines D and L (both inactive
and active forms). However, PPARg knockdown did not
modify these increases, suggesting that PPARg does not
regulate cathepsin L or D in this model. Cysteine cathepsins
are optimally active in a slightly acidic pH, and are mostly
unstable at neutral pH. When cathepsins are outside the
lysosomes or if there is no acidic pH within the lysosome, they
can be relatively rapidly inactivated and proenzymes accu-
mulate.28 As SiControl and SiPPARg-untreated or cannabi-
noid-treated cells had a right cleavage of these proteases and
the same level of the lysosomal marker LAMP-2, we can
conclude that lysosomes work correctly, suggesting that the
reason for autophagosome accumulation is not lysosome
failure. This is in concordance with the observation that
PPARg silencing causes an accumulation of LC3 even in
control cells (Figures 4a and b). Therefore, we can conclude
that in HCC cells cannabinoids induce autophagy through
PPARg activation (summarized in Figure 4d).
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Figure 5 PPARg is involved in cannabinoid-induced cell death. (a) HepG2 or HuH7 cells were incubated with different doses of THC or JWH-015 for 48 h in the presence
or absence of 3 mM GW9662 (GW) and cell viability was assayed by MTT. Results are shown as the mean±S.D. of three different experiments, each performed in triplicate.
*Po0.05 and **Po0.01 as compared with cannabinoid-treated cells by Student’s t-test. (b and c) HepG2 cells transfected either with control siRNA or PPARg-selective
siRNA (siPPARg) were incubated with 8mM THC or 8mM JWH-015 (JWH) for 48 h and cell viability was assayed by MTT. Results are shown as the mean±S.D. of five
different experiments (**Po0.01 as compared with control cells and ##Po0.01 as compared with siControl cannabinoid-treated cells by Student’s t-test). (c) HepG2 cells
were incubated with different doses of Troglitazone for 48 h and cell viability was assayed by MTT. (d) HepG2 cells were incubated with THC (2 mM), JWH (2 mM), Troglitazone
(20mM) or THC plus Troglitazone for 48 h and cell viability was assayed by MTT
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PPARc participates in the antiproliferative effect evoked
by cannabinoids. It has been recently described that the
cannabinoid WIN induces apoptosis through PPARg in
HepG2 cells.18 Moreover, in previous studies, we demon-
strated that cannabinoids induce apoptosis and autophagy in
HCC cells and in xenograft tumor models. To investigate the
role of PPARg in the anti-proliferative response exerted by
THC or JWH-015, HCC cells were incubated with increasing
doses of both cannabinoids for 48 h in the presence of the
PPARg-selective antagonist GW9669 and cell viability was
measured by MTT. Pharmacological inhibition of PPARg
caused a shift of the dose–response curve to the right, thus
increasing the IC50 dose in HepG2 and in HUH-7 cells
(Figure 5a). Moreover, when HepG2 cells or HuH-7 cells
were transfected with PPARg siRNA, the inhibitory effect of
cannabinoids on cell viability was reduced (Figure 5b). As
PPARg agonists have been evaluated as potential anti-
tumoral agents, we decided to test the possible synergic
effect between cannabinoids and the PPARg agonist
Troglitazone (TRO) in combinatorial treatment. In agreement
with the results obtained by other groups,16,29–33 we
observed that TRO treatment produced a dose-dependent
reduction in cell viability that reached a value of 50% when
40mM concentrations were used (Figure 5c). We therefore
selected submaximal doses of Troglitazone (20 mM), THC
(2mM) and JWH-015 (2mM) to evaluate whether the
combined administration of PPAR ligands and cannabinoids
enhanced their ability to reduce cell viability. In line with this
possibility, combined treatment with low doses of TRO and
THC or JWH-015 reduced the viability of HepG2 cells
(Figure 5d).
To further investigate the role of PPARg in cannabinoid-
induced cell death, we measured the number of apoptotic
Anexin-V and IP-stained cells by cytometry. Both THC and
JWH-015 increased the number of apoptotic cells, which was
reduced by pharmacological inhibition of PPARg with
GW9669 (Figure 6). According to this, GW9669 also reduced
the cleavage of procaspase 3 induced by cannabinoids (data
not shown). These observations support the fact that PPARg
participates in cell death induced by cannabinoids.
PPARc is involved in the in vivo antitumor properties of
cannabinoids. As a further proof for the involvement of
PPARg in the antitumoral action of cannabinoids, we
generated tumor xenografts by subcutaneous inoculation of
HepG2 cells in nude mice. Mice were treated peritumorally
with THC or JWH-015 alone or in combination with the
PPARg inhibitor GW9662, and tumor size was daily
monitored. As shown in Figure 7, THC and JWH-015
significantly reduced the tumor growth rate. However, when
tumors were treated with the cannabinoids in the presence of
the PPARg antagonist, the tumor growth was similar to those
of the controls. Furthermore, we analyzed PPARg mRNA
expression of HepG2- and HuH-7-derived tumors, and we
found that cannabinoid treatment increased PPARg mRNA
levels in both cases (Figure 7b). Thereby, in vivo antitumor
effect of cannabinoids in HCC cells depends on PPARg
activation.
Discussion
The prevalence and severity of HCC is increasing worldwide
and prognosis of HCC patients is still unsatisfactory owing to
the high rate of recurrence and metastasis. Therefore, the
improvement of therapeutic strategies for HCC patients is
critical for the management of HCC. The active ingredients of
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Cannabis sativa plant, as well as their synthetic analogues,
emerge nowadays as new anticancer drugs as they exert
antitumor properties in a wide range of tumor cell types
including HCC cells. During the past few years, much effort
has been taken to understand the molecular mechanisms
involved in the antitumoral action of cannabinoids. We have
recently published that THC and JWH-015 induce autophagy
in HCC cells by activating the AMPK pathway.19 In this study,
we report the involvement of PPARg activation in the antic-
ancer effect of cannabinoids. We show that both THC and
JWH-015 increase mRNA and protein levels of PPARg in a
time-dependent fashion and induce PPAR activation in vitro.
The activation of PPARg is not produced by direct binding of
cannabinoids to PPARg. It has been shown that PPARg may
be phosphorylated by different kinases including AMPK,
which can modulate PPARg activity.21 As we had previously
observed that cannabinoids induce AMPK activation in HCC
cells, we wonder whether AMPK was responsible for
cannabinoid-induced PPARg activation. However, genetic
downregulation of AMPK did not have any effect on PPARg
induction exerted by cannabinoids. Moreover, genetic inhibi-
tion of PPARg did not have any effect on AMPK phosphoryla-
tion or Akt/mTOR/S6 axis activation in cannabinoid-treated
cancer cells, suggesting that PPARg did not have a role in
those pathways. Therefore, although modulation of both
AMPK and PPARg signalling might be responsible for the
antiproliferative effect of cannabinoids, a cross talk between
them was not found in our study (summarized in Figure 4d).
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Our results are in contrast with recent research showing
that activation of AMPK inhibits transcriptional activity of
PPARg in HepG2 cells.34 However, in this study, the effects
of AMPK did not appear to be mediated through effects
on PPARg binding to DNA andwere independent of the kinase
activity.34
The role of PPARg in cannabinoid-induced cell death was
primarily concluded from the pharmacological blockage of cell
death by compound GW9662, a PPARg selective antagonist,
and further confirmed by knockdown of PPARg expression. In
line with this, previous data have evidenced a PPARg-
dependent process in WIN-induced HepG2 cell death.18
However, in vivo involvement of PPARg in the cannabinoids’
antitumoral action has not been demonstrated before. We
show here that pharmacological inhibition of PPARg in vivo
blocks the antitumoral effect of cannabinoids in HCC
xenografts.
The antitumor activity of cannabinoids against HCC cells
has been related to the ability of these drugs to induce
apoptosis and autophagy. Our results show that when PPARg
is inhibited with GW9662 or genetically knocked down,
cannabinoids fail to induce apoptosis. To note, when PPARg
expression is silenced, there is an increase of LC3-II and p62,
not only in the cannabinoid-treated cells but even in the control
cells. This suggests that when PPARg is absent, autophagy is
blocked after autophagosome formation and therefore LC3II
increases and p62 accumulates in the autophagosome
because it cannot be further degraded (Figure 4d). Our
studies about lysosomal functionality suggest that this
organelle operates appropriately, because procathepsins
are cleaved and lysosomes are not accumulated. Studies
performed by Jiang et al.24 in PPARg-deficient mice showed
accumulated autophagic vacuoles and upregulated autopha-
gic marker LC3 protein expression. This is in agreement with
our observations, which provide a mechanistic link between a
PPARg receptor and autophagy-essential proteins in mam-
malian hepatocellular cells. These results are in line with a
recent study showing a specific induction of autophagy by
PPARg activation in breast cancer cells.23
It has been previously described that cannabinoids cause
endoplasmic reticulum stress and increase of the pseudoki-
nase protein TRIB3, which links ER stress to autophagy in
cannabinoids’ antitumoral action.25,35,36 Our results show that
when TRIB3 is genetically inhibited, it dramatically decreases
the expression of both PPARg mRNA and protein. Recent
studies performed by Takahashi et al.22 demonstrated that
TRIB3 downregulates PPARg transcriptional activities by
protein–protein interaction in 3T3-L1 adipocytes. Moreover,
it has previously been shown that ceramide induces
HepG2 cell apoptosis through PPARg activation.37 Our data
show that cannabinoid treatment increases phosphory-
lated-eIF2a, an ER stress marker, and that the ER
stress-related pseudokinase TRIB3 is necessary for
cannabinoid-induced cell death and PPARg activation. We
have also observed that cannabinoids induce ceramide
accumulation in HepG2 cells (data not shown), which could
link cannabinoid-induced ER stress with inhibition of cell
proliferation via PPARg activation. Here, we provide the
first evidence that TRIB3 has a crucial role in regulating
cannnabinoid-induced PPARg overexpression.
Materials and Methods
Reagents. THC was obtained from THC Pharm GmbH (Frankfurt, Germany)
and JWH-015 was purchased from Sigma (St. Louis, MO, USA). Both
cannabinoids were dissolved in DMSO. The final concentration of the DMSO in
the cell cultures was never 40.1%. The same quantity of DMSO was added to
controls. The anti-PPARg, anti-peiF2a, anti-pAMPK, anti-pS6, anti-pAKT-ser473
and anti-p62 polyclonal antibodies were obtained from Cell Signaling Technology
(Danvers, MA, USA). The anti-LC3 polyclonal antibody was obtained from MBL
International (Woburn, MA, USA) and procaspase 3, anti-cathepsin D and anti-
cathepsin L were obtained from Santa Cruz Biotechnology (Bergheimer,
Heidelberg, Germany). The PPARg antagonist GW9662, the agonist Troglitazone
and all other reagents were purchased from Sigma.
Cell cultures. Human HCC HepG2 cells (ATCC HB-8065, Rockville, MD,
USA) and human hepatoma HuH-7 cells (kindly supplied by Dr. Lisardo Bosca´,
Instituto de Investigaciones Biome´dicas Alberto Sols, Madrid, Spain), were
maintained in DMEM medium containing 10% fetal bovine serum, 1% penicillin/
streptomycin (Invitrogen, Paisley, UK) and 1 non-essential amino acids. Cells
were seeded at a density of 5000 cells/cm2. Sixteen hours post-seeding, medium
was changed to 0.5% FBS medium and experiments were performed 24 h later,
when cells were 80% confluent.
Quantitative PCR. Total RNA was isolated from cells by Trizol Reagent from
Gibco (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s protocol.
One microgram total RNA was retrotranscribed to cDNA with the M-MLV Reverse
transcriptase kit (Life Technologies, Carlsbad, CA, USA). Real-time quantitative
PCR assays were performed using the FastStart Universal Probe Master mix with
Rox (Roche Applied Science, Barcelona, Spain), and probes were obtained from
the Universal Probe Library Set (Roche Applied Science); TRIB3 sense primer,
50-GCCACTGCCTCCCGTTCTTG-30; TRIB3 antisense primer, 50-GCTGCCTTGCC
CGAGTATGA-30; PPARg sense primer, 50-GGCGAGGGCGATCTTGACAGG-30;
PPARg antisense primer, 50-TGCGGATGGCCACCTCTTTGC-30. CD36 sense
primer, 50-AGTCACTGCGACATGATTAATGGT-3´; CD36 antisense primer, 50-CTG
CAATACCTGGCTTTTCTC-30.
Western blot. After different treatments according to the experiments, cells
were lysed in ice-cold lysis buffer (50 mM Tris pH 7.4, 0.8 M NaCl, 5 mM MgCl2,
0.1% Triton X-100, 1 mM PMSF, 10 mg/ml soybean trypsin inhibitor, 1 mg/ml
aprotinin and 5 mg/ml leupeptin), and cleared by microcentrifugation. Equivalent
protein amounts of each sample were separated on SDS-PAGE gels and blotted
to PVDF transfer membrane. After blocking with 5% skim-dried milk, immunoblot
analysis was performed followed by enhanced chemoluminescence detection as
previously described.38
DNA-binding ELISA for activated PPARc transcription factor.
Cells were treated with cannabinoids as explained in the figure legends, and
scraped on washing buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM, KCl, 1 mM
DTT, 0.5 mM PMSF, 5 mM NaF, 2mg/ml leupeptin, 10mg/ml aprotinin), and then
lysed in washing bufferþ 0.5% NP-40 for 30 min at 4 1C. Then, the nuclear extract
was obtained by centrifugation at 15 000 g for 30 min at 4 1C. To determine
whether the treatment activated PPARg, 10mg nuclear extract was incubated in a
96-well plate to which oligonucleotide containing the peroxisome proliferator
response element had been immobilized (Active Motif, Rixensart, Belgium). PPARs
contained in nuclear extracts bind specifically to this oligonucleotide and are
detected through use of an antibody directed against PPARg. Addition of a
secondary antibody conjugated to horseradish peroxidase provides a sensitive
colorimetric readout that is quantified by spectrophotometry. Unspecific binding is
monitored by competition with an oligonucleotide containing the consensus PPARg
response element sequence, according to the manufacturer’s protocol.
PPAR binding assay. To test the binding capacity of JWH-015 to PPARg,
HeLa cell lines expressing a chimeric protein containing the ligand-binding domain
of human PPARg were used. The ligand-binding domain of PPARg was fused to
the yeast transactivator GAL4 DNA-binding domain. HeLa cells contained a
luciferase reporter gene driven by a GAL4 recognition sequence. HeLa cells were
treated and binding to PPARg was estimated according to luciferase activity
(relative light units normalized against the reference compound BRL49653).
Oil red o staining. Oil Red O staining was performed after cell treatment with
cannabinoids. Briefly, the cells were washed with phosphate-buffered saline twice,
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fixed with 10% formalin for 30 min, and stained with Oil Red O for 1 h. After wash
with phosphate-buffered saline, the stained lipid droplets were dissolved in
isopropanol and quantified at 540 nm.
Confocal microscopy. After 48 h in culture, the cells were fixed in 4%
paraformaldehyde in phosphate-buffered saline and incubated. Immunolabelling of
neutral lipid with Lipidtox (Invitrogen) was performed by incubation at room
temperature for 1 h. Imaging was with a Leica TCS SP5 laser-scanning confocal
microscope with LAS-AF imaging software, using a  63 oil objective.
Cell viability assay. Cells in logarithmic phase were cultured at a density of
5000 cells/cm2 in a 12-well plate. After treatments, as explained in the figure
legends, cell viability was assayed by MTT as previously described,19,39 to
evaluate the effects of cannabinoids on cell growth.
siRNA tranfections. Cells were then transfected in 1 ml OPTIMEN contain-
ing 4 mg lipofectamine 2000 (Invitrogen), with 100 nM PPARg, AMPK or TRIB3
specific siRNA duplexes (PPARg: 50-CCAAGUUUGAGUUUGCUGUdTdT-30 and
50-ACAGCAAACUCAAACUU GGdTdT-30; AMPK: 50-CCCAUAUUAUUUGCGU-
GUAdTdT-30 and 50-UACACGCCAAAUAAUAUGGGdTdT-30; TRIB3: 50-GUGC-
GAAGCCGCCAC CGUAdTdT-30 and 50-UACGGUGGCGGCUUCGCACdTdT-30)
(Sigma) or control scrambled RNA for 12 h according to the manufacturer’s
protocols (Invitrogen). At 24 h after transfection, the medium was removed and
replaced for DMEM containing 10% fetal bovine serum. At dedicated time points
after transfection, cells were used for MTT cell viability assays or western blot.
PPAR gamma expression vector and transient transfections.
The PPARg expression vector pCMX-mPPARg was generously provided by
Dr. Mercedes Ricote (CNIC, Madrid, Spain). HepG2 cells were transiently
transfected using 4ml Lipofectamine LTX & Plus Reagent (Invitrogen) with 3mg of
the expression vector in 0.2-ml OPTIMEN, according to the manufacturer’s
protocols (Invitrogen). At 48 h after transfection, the experiments were performed
with the different treatments.
Animal study. Forty-eight (48) male athymic nude (nu/nu) mice aged 5 weeks
were purchased from Harlan Iberica Laboratory (Barcelona, Spain) and housed
under specific pathogen-free conditions in a 12-h light–dark cycle at 21–23 1C and
40–60% humidity. All animal studies were conducted in accordance with the
Spanish institutional regulation for the housing, care and use of experimental
animals with the approval of the Institutional Animal Care and Use Committee of
Alcala University and met the European Community directives regulating animal
research. Recommendations made by the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR) have been kept carefully.
After 1 week adaptation period, mice were injected subcutaneously in the right
flank with 10 106 HepG2 cells in 0.1 ml of phosphate-buffered salineþ 0.5% BSA
to induce HCC tumors. Two weeks after transplantation, tumors had grown to an
average volume of 150 mm3. Then, the mice were equally divided into six groups
(n¼ 8) and daily treated with vehicle, 15 mg/kg THC or 1.5 mg/kg JWH-015 in the
presence or absence of 1 mg/kg GW9662 for 15 days. After treatment, tumors were
dissected and weighed.
Statistical analysis. Data are presented as the mean±S.E. of the number
of experiments indicated. Significance of differences between groups was tested
by paired Student’s t-test using the SPSS statistical software (Chicago, IL, USA).
Differences between groups were considered significant when Po0.05.
Conclusions
We here illustrate that the cannabinoids THC and JWH-015 exert antitumor effect
against the human HCC cell lines HepG2 and HUH-7 in vitro and in vivo through
PPARg. The activation of PPARg by cannabinoids is independent of the signaling
cascades previously described. However, it links endoplasmic reticulum stress with
autophagy. TRIB3 is necessary for PPARg expression in HCC cells, which
collaborates in the autophagy flux.
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